SK11452002A3 - Deriváty piperazínu a piperidínu na použitie pri liečení alebo prevencii poškodenia neurónov - Google Patents
Deriváty piperazínu a piperidínu na použitie pri liečení alebo prevencii poškodenia neurónov Download PDFInfo
- Publication number
- SK11452002A3 SK11452002A3 SK1145-2002A SK11452002A SK11452002A3 SK 11452002 A3 SK11452002 A3 SK 11452002A3 SK 11452002 A SK11452002 A SK 11452002A SK 11452002 A3 SK11452002 A3 SK 11452002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- group
- straight
- branched
- alkyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18194400P | 2000-02-11 | 2000-02-11 | |
| US24733000P | 2000-11-10 | 2000-11-10 | |
| PCT/US2001/004210 WO2001058891A2 (en) | 2000-02-11 | 2001-02-09 | Piperazine and piperidine derivatives for treatment or prevention of neuronal damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK11452002A3 true SK11452002A3 (sk) | 2003-03-04 |
Family
ID=26877657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1145-2002A SK11452002A3 (sk) | 2000-02-11 | 2001-02-09 | Deriváty piperazínu a piperidínu na použitie pri liečení alebo prevencii poškodenia neurónov |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP1257544B1 (ru) |
| JP (1) | JP2003522767A (ru) |
| KR (1) | KR20020073586A (ru) |
| CN (1) | CN1210274C (ru) |
| AP (1) | AP2002002596A0 (ru) |
| AU (1) | AU4146401A (ru) |
| BR (1) | BR0108175A (ru) |
| CA (1) | CA2398822A1 (ru) |
| CO (1) | CO5261503A1 (ru) |
| CZ (1) | CZ20022720A3 (ru) |
| EA (1) | EA200200847A1 (ru) |
| EE (1) | EE200200442A (ru) |
| HR (1) | HRP20020737A2 (ru) |
| HU (1) | HUP0301391A3 (ru) |
| IL (1) | IL150849A0 (ru) |
| IS (1) | IS6477A (ru) |
| MX (1) | MXPA02007790A (ru) |
| NO (1) | NO20023787L (ru) |
| NZ (1) | NZ520638A (ru) |
| PE (1) | PE20011081A1 (ru) |
| PL (1) | PL357177A1 (ru) |
| SK (1) | SK11452002A3 (ru) |
| WO (1) | WO2001058891A2 (ru) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6809093B2 (en) * | 2000-10-17 | 2004-10-26 | H. Lee Moffitt Cancer & Research Institute, Inc. | 2-substituted heterocyclic compounds |
| HUP0303376A3 (en) * | 2001-02-28 | 2007-08-28 | Merck & Co Inc | Acylated piperidine derivatives as melanocortin-4 receptor agonists, and pharmaceutical compositions containing them and use thereof |
| AU2002250343B2 (en) | 2001-02-28 | 2006-05-25 | Merck Sharp & Dohme Corp. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| ES2272703T3 (es) | 2001-02-28 | 2007-05-01 | MERCK & CO., INC. | Derivados de piperidina acilados como agonistas de receptor de melanocortina-4. |
| DE60229393D1 (de) | 2001-07-18 | 2008-11-27 | Merck & Co Inc | Überbrückte piperidinderivate als melanocortin-rezeptor-agonisten |
| JP4320252B2 (ja) * | 2001-09-06 | 2009-08-26 | シェーリング コーポレイション | アンドロゲン依存性疾患の処置のための１β−ヒドロキシステロイドデヒドロゲナーゼ３型インヒビター |
| WO2003037338A2 (en) * | 2001-11-01 | 2003-05-08 | Vertex Pharmaceuticals Incorporated | Modulators of the cholesterol biosynthetic pathway |
| US7414057B2 (en) | 2002-09-11 | 2008-08-19 | Merck & Co., Inc. | Piperazine urea derivatives as melanocortin-4 receptor agonists |
| US20040180880A1 (en) * | 2002-10-03 | 2004-09-16 | Lauffer David J. | Piperazine and piperidine derivatives |
| AR043434A1 (es) | 2003-03-03 | 2005-07-27 | Merck & Co Inc | Derivados de piperizacina acilados como agonistas del receptor de melanocortina-4. composiciones farmaceuticas y usos |
| EP2617419A1 (en) | 2003-04-24 | 2013-07-24 | Incyte Corporation | Aza spiro alkane derivatives as inhibitors of metallproteases |
| EP1524265A1 (en) * | 2003-10-15 | 2005-04-20 | Newron Pharmaceuticals S.p.A. | Prolinamide derivatives as sodium and/or calcium channel blockers or selective MAO-B inhibitors |
| JP2008506779A (ja) | 2004-07-19 | 2008-03-06 | メルク エンド カムパニー インコーポレーテッド | メラノコルチン−４受容体作用薬としてのアシル化ピペリジン誘導体 |
| GB0508319D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
| US7408066B2 (en) | 2005-06-20 | 2008-08-05 | Schering Corproation | Carbon-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists |
| CA2610959A1 (en) | 2005-06-20 | 2007-01-04 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
| GB0514018D0 (en) * | 2005-07-07 | 2005-08-17 | Ionix Pharmaceuticals Ltd | Chemical compounds |
| EP1988920A1 (en) | 2006-02-02 | 2008-11-12 | Rinat Neuroscience Corp. | Methods for treating obesity by administering a trkb antagonist |
| CA2663984C (en) | 2006-10-18 | 2012-02-21 | Pfizer Products Inc. | Biaryl ether urea compounds |
| JP5514831B2 (ja) | 2008-11-17 | 2014-06-04 | メルク・シャープ・アンド・ドーム・コーポレーション | 糖尿病の治療のための置換二環式アミン |
| CA2768577A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
| WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
| US9365539B2 (en) | 2010-05-11 | 2016-06-14 | Merck Sharp & Dohme Corp. | Prolylcarboxypeptidase inhibitors |
| EP2579873A4 (en) | 2010-06-11 | 2013-11-27 | Merck Sharp & Dohme | NOVEL PROLYLCARBOXYPEPTIDASE HEMMER |
| US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
| CN105636953B (zh) * | 2013-07-31 | 2018-01-02 | 诺华股份有限公司 | 1,4‑二取代的哒嗪衍生物及其用于治疗与smn缺乏相关的病症的用途 |
| JP6985179B2 (ja) * | 2018-02-27 | 2021-12-22 | 田辺三菱製薬株式会社 | プロリンアミド化合物の製造方法 |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| KR20220030222A (ko) | 2019-05-31 | 2022-03-10 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791501A (fr) * | 1971-11-19 | 1973-05-17 | Albert Ag Chem Werke | Diamines cycliques n,n'-disubstituees et leur procede de preparation |
| US3862937A (en) * | 1972-02-23 | 1975-01-28 | Univ Mississippi | 6-Phenethyl-3-piperidinecarboxamides |
| FR2597100A1 (fr) * | 1986-01-21 | 1987-10-16 | Nippon Shinyaku Co Ltd | Derives du pyroglutamide |
| US4745123A (en) * | 1986-02-18 | 1988-05-17 | Warner-Lambert Company | Substituted tetrahydro-3-pyridine-carboxylic acid, ester, and amide cholinergic agents |
| NZ228329A (en) * | 1988-03-18 | 1991-12-23 | Mitsui Toatsu Chemicals | Catechol derivatives and pharmaceutical compositions thereof |
| US5232923A (en) * | 1988-03-18 | 1993-08-03 | Mitsui Toatsu Chemicals, Incorporated | Catechol derivatives and pharmaceutical preparations containing same |
| US5290793A (en) * | 1989-09-12 | 1994-03-01 | Mitsui Toatsu Chemicals, Incorporated | Dihydrocaffeic acid derivatives and pharmaceutical preparation containing same |
| FR2705095B1 (fr) | 1993-05-12 | 1995-06-23 | Adir | Nouveaux indoles substitués, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5614547A (en) | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US5811434A (en) * | 1996-11-13 | 1998-09-22 | Vertex Pharmacueticals Incorporated | Methods and compositions for stimulating neurite growth |
| AR010744A1 (es) * | 1996-12-09 | 2000-07-12 | Guildford Pharmaceuticals Inc | Inhibidores polipropilos de ciclofilina |
| JPH11106375A (ja) * | 1997-08-18 | 1999-04-20 | Pfizer Pharmaceut Inc | ブラジキニンアンタゴニストとしての光学的に活性な１，４−ジヒドロピリジン化合物 |
-
2001
- 2001-02-09 IL IL15084901A patent/IL150849A0/xx unknown
- 2001-02-09 EP EP01912714A patent/EP1257544B1/en not_active Expired - Lifetime
- 2001-02-09 JP JP2001558441A patent/JP2003522767A/ja active Pending
- 2001-02-09 SK SK1145-2002A patent/SK11452002A3/sk not_active Application Discontinuation
- 2001-02-09 KR KR1020027010367A patent/KR20020073586A/ko not_active Application Discontinuation
- 2001-02-09 NZ NZ520638A patent/NZ520638A/en unknown
- 2001-02-09 HU HU0301391A patent/HUP0301391A3/hu unknown
- 2001-02-09 CA CA002398822A patent/CA2398822A1/en not_active Abandoned
- 2001-02-09 EE EEP200200442A patent/EE200200442A/xx unknown
- 2001-02-09 CO CO01009891A patent/CO5261503A1/es unknown
- 2001-02-09 PE PE2001000144A patent/PE20011081A1/es not_active Application Discontinuation
- 2001-02-09 PL PL01357177A patent/PL357177A1/xx not_active Application Discontinuation
- 2001-02-09 CZ CZ20022720A patent/CZ20022720A3/cs unknown
- 2001-02-09 CN CNB018048021A patent/CN1210274C/zh not_active Expired - Fee Related
- 2001-02-09 BR BR0108175-6A patent/BR0108175A/pt not_active IP Right Cessation
- 2001-02-09 AU AU41464/01A patent/AU4146401A/en not_active Abandoned
- 2001-02-09 EA EA200200847A patent/EA200200847A1/ru unknown
- 2001-02-09 WO PCT/US2001/004210 patent/WO2001058891A2/en active IP Right Grant
- 2001-02-09 MX MXPA02007790A patent/MXPA02007790A/es unknown
- 2001-02-09 AP APAP/P/2002/002596A patent/AP2002002596A0/en unknown
-
2002
- 2002-07-19 IS IS6477A patent/IS6477A/is unknown
- 2002-08-09 NO NO20023787A patent/NO20023787L/no unknown
- 2002-09-09 HR HR20020737A patent/HRP20020737A2/hr not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20023787L (no) | 2002-10-11 |
| AU4146401A (en) | 2001-08-20 |
| NO20023787D0 (no) | 2002-08-09 |
| BR0108175A (pt) | 2003-01-28 |
| AP2002002596A0 (en) | 2002-09-30 |
| CZ20022720A3 (cs) | 2002-11-13 |
| KR20020073586A (ko) | 2002-09-27 |
| MXPA02007790A (es) | 2002-10-17 |
| EP1257544A2 (en) | 2002-11-20 |
| CN1404477A (zh) | 2003-03-19 |
| CA2398822A1 (en) | 2001-08-16 |
| WO2001058891A3 (en) | 2002-04-25 |
| NZ520638A (en) | 2004-05-28 |
| IS6477A (is) | 2002-07-19 |
| CN1210274C (zh) | 2005-07-13 |
| WO2001058891A2 (en) | 2001-08-16 |
| IL150849A0 (en) | 2003-02-12 |
| PE20011081A1 (es) | 2001-10-22 |
| EE200200442A (et) | 2003-12-15 |
| HUP0301391A2 (hu) | 2003-08-28 |
| EP1257544B1 (en) | 2012-07-25 |
| HRP20020737A2 (en) | 2005-10-31 |
| CO5261503A1 (es) | 2003-03-31 |
| HUP0301391A3 (en) | 2010-03-29 |
| JP2003522767A (ja) | 2003-07-29 |
| EA200200847A1 (ru) | 2003-02-27 |
| PL357177A1 (en) | 2004-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK11452002A3 (sk) | Deriváty piperazínu a piperidínu na použitie pri liečení alebo prevencii poškodenia neurónov | |
| US20040034019A1 (en) | Piperazine and piperidine derivatives | |
| US6528533B2 (en) | Azo amino acids derivatives | |
| US6849630B2 (en) | Cyclized amino acid derivatives | |
| EP1546103B1 (en) | Piperazine and piperidine derivatives for treatment of neurological diseases | |
| US6949655B2 (en) | Acyclic piperidine derivatives | |
| JP2006504717A5 (ru) | ||
| US20030144253A1 (en) | Acyclic and cyclic amine derivatives | |
| US20030191110A1 (en) | Modulators of the cholesterol biosynthetic pathway | |
| US6552041B2 (en) | Cyclized amide derivatives | |
| US6677359B2 (en) | N-substituted glycine derivatives | |
| US6747042B2 (en) | N-heterocyclic derivatives | |
| ZA200205933B (en) | Piperazine and piperidine derivatives. | |
| AU2002344734A1 (en) | Acylic piperazine and piperidine derivatives which are useful for treating neuronal damage |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC9A | Refused patent application |